122 related articles for article (PubMed ID: 36579364)
21. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
22. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
23. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
24. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG
Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125
[TBL] [Abstract][Full Text] [Related]
25. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma.
Xu H; Wang W; Yin J; Song C; Li L; Sun Z
Drug Des Devel Ther; 2022; 16():4269-4277. PubMed ID: 36540715
[TBL] [Abstract][Full Text] [Related]
27. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
[TBL] [Abstract][Full Text] [Related]
28. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
29. Sequential combined modality therapy for stage III non-small cell lung cancer.
Vokes EE
Hematol Oncol Clin North Am; 1990 Dec; 4(6):1133-42. PubMed ID: 1962780
[TBL] [Abstract][Full Text] [Related]
30. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
32. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
33. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
34. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stage Ib2 and IIa cervical squamous cell cancer patients.
Liang Y; Lü B; Chen X; Qin J; Cheng X; Xie X; Lü W
Virchows Arch; 2016 Mar; 468(3):329-36. PubMed ID: 26637198
[TBL] [Abstract][Full Text] [Related]
36. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
37. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
[TBL] [Abstract][Full Text] [Related]
38. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
39. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
40. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
